Stock screenerAll disclosures →
EDGAR →
EDIT
Conviction 47HealthcareScan · Mon, Aug 10, 2026EDIT$2.81-2.43%
ResistanceSupportVol 14Insider sell3
Vol MA14 1.66M
May 11May 28Jun 16Jul 6Jul 23Aug 10
WSB mentions · 24h changelatest -25.00%· 3 mentions
May 11May 28Jun 16Jul 6Jul 23Aug 10
Price2.81
Change-2.43%
Gap-1.74%
Rel volume2.53×
Avg volume1.62M
Avg $ vol4.55M
SMA 202.79
SMA 502.90
SMA 2002.60
Price vs 50-3.01%
Price vs 200+7.95%
MA stackmixed
50/200 cross—
Supertrenddown · 3.12
RSI (14)48
MACD hist0.02
MACD crossbull · 2d
Stoch %K / %D47 / 55
ADX (14)20
+DI / −DI24 / 21
RSI divergenceBullish
MACD divergenceBullish
ATR %+6.87%
ADR %5.74%
52w high4.15
52w low1.67
From 52w high-32.29%
Above 52w low+68.77%
New 52w highNo
SqueezeOff
Bollinger width22.06%
%B0.53
Donchian pos42.04%
Donchian high3.21
Donchian low2.52
AVWAP (52w high)2.80
vs AVWAP high+0.21%
AVWAP (52w low)2.82
vs AVWAP low-0.30%
OBV trendDown
Chaikin MF (20)-0.23
Today vs 20d2.53×
Avg vol (14d)1.66M
Avg vol (20d)1.62M
Avg $ vol (20d)4.55M
Market cap—
RS 3m (vs SPY)-10.65%
RS 6m (vs SPY)+58.86%
RS line new highNo
Trend template4/8
Technical rank57.0
1 week+6.04%
1 month-13.80%
3 months-9.65%
6 months+54.40%
1 year+12.85%
YTD+37.07%
P/E-2.76
P/B4.19
P/S10.90
P/FCF-2.66
EPS-1.80
Div yield—
ROE-152.03%
ROA-67.43%
Debt/Eq0.53
Current3.19
EV/EBITDA—
Gross margin—
Net margin-395.01%
Rev growth25.39%
EPS growth32.49%
Price target—
Target upside—
Analyst rating—
Institutional—
Ent. value315.47M
Revenue11.89M
Net income-18.23M
Gross profit—
Free cash flow-165.85M
IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
ExchangeNasdaq
Shares out97.91M
Employees87
ListedWed, Feb 3, 2016
Free float—
Float %—
Short interest—
Days to cover—
Short volume—
Squeeze score—
Next earnings—
EPS forecast—
Last EPS vs est—
Last surprise—
Setup gradeC
Conviction47 / 100
Pattern quality—
Tech rank57.0 / 100
Group rank86 / 100 · Leading
Status laneNo active setup
Setup direction—
Pattern family
Resistance3.82
Support2.44
Days since event—
Candle confirm—
News sentiment—
Financials as of Tue, Jun 30, 2026 · quarterly.
Congress activity
Disclosed STOCK Act trades in EDIT
No recent disclosed trades by Congress in EDIT. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in EDIT · 6 buys · 4 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Ellinor Patrick Thomas II Director · Stock Option (right to buy) · 2026-08-06 | Grant | 103.4K | — | 2026-08-06 | 2026-08-07 |
Parison Amy SVP, Chief Financial Officer · Common Stock · 2026-08-03 | Sell | 678 | $2K | 2026-08-03 | 2026-08-05 |
Connaughton Bernadette Director · Stock Option (right to buy) · 2026-06-17 | Grant | 51.7K | — | 2026-06-17 | 2026-06-22 |
Levy Elliott M. Director · Stock Option (right to buy) · 2026-06-17 | Grant | 51.7K | — | 2026-06-17 | 2026-06-22 |
Scadden David Director · Stock Option (right to buy) · 2026-06-17 | Grant | 51.7K | — | 2026-06-17 | 2026-06-22 |
Hirsch Andrew Director · Stock Option (right to buy) · 2026-06-17 | Grant | 51.7K | — | 2026-06-17 | 2026-06-22 |
Hopfield Jessica Director · Stock Option (right to buy) · 2026-06-17 | Grant | 51.7K | — | 2026-06-17 | 2026-06-22 |
Burkly Linda EVP, CHIEF SCIENTIFIC OFFICER · Common Stock · 2026-06-03 | Sell | 731 | $2K | 2026-06-03 | 2026-06-05 |
O'Neill Gilmore Neil CEO · Common Stock · 2026-06-03 | Sell | 15.38K | $42K | 2026-06-03 | 2026-06-05 |
Parison Amy SVP, Chief Financial Officer · Common Stock · 2026-06-03 | Sell | 464 | $1K | 2026-06-03 | 2026-06-05 |
SEC filings
EDGAR filings in EDIT · 8 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.